Maximum quantity allowed is 999
Please select the quantity
CAS RN: 82159-09-9 | Product Number: E0906
Epalrestat
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 1G |
$49.00
|
5 | 15 | Contact Us | |
| 5G |
$155.00
|
20 | 19 | Contact Us |
* Please contact our distributors or
TCI
to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.
| Product Number | E0906 |
Purity / Analysis Method 
|
>98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__1__5H__1__3NO__3S__2 = 319.39 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature
|
Room Temperature (Recommended in a cool and dark place, <15°C) |
| Packaging and Container
|
1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 82159-09-9 |
| Reaxys Registry Number | 4236712 |
| PubChem Substance ID | 172089065 |
| Merck Index (14) | 3605 |
| MDL Number | MFCD00865484 |
Specifications
| Appearance | Light yellow to Amber to Dark green powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Melting point | 222.0 to 226.0 °C |
Properties (reference)
| Melting Point | 224 °C |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H300 : Fatal if swallowed. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. P405 : Store locked up. |
Related Laws:
| RTECS# | XJ5131855 |
Transport Information:
| UN Number | UN2811 |
| Class | 6.1 |
| Packing Group | II |
| H.S.code* | 2934.10-000 |
Application
Aldose Reductase (AR) Inhibitor
References
- Effects of a new aldose reductase inhibitor on various tissues in vitro
- H Terashima, K Hama, R Yamamoto, M Tsuboshima, R Kikkawa, I Hatanaka, Y Shigeta, J. Pharmacol. Exp. Ther. 1984, 229, 226.
- Epalrestat, an aldose reductase inhibitor, reduces the levels of Nepsilon-(carboxymethyl) lysine protein adducts and their precursors in erythrocytes from diabetic patients
- An aldose reductase inhibitor prevents glucose-induced increase in transforming growth factor-β and protein kinase C activity in cultured human mesangial cells
- Molecular modeling studies of the binding modes of aldose reductase inhibitors at the active site of human aldose reductase
- Aldose reductase structures: Implications for mechanism and inhibition
- Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy
- M. A. Ramirez, N. L. Borja, Pharmacotherapy 2008, 28, 646.
PubMed Literature
Documents
Product Articles
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.